European Biotech Acquisition Corp. Receives Expected Notific

European Biotech Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report
European Biotech Acquisition Corp. (the "Company") today announced it received a notice on May 28, 2021 from the Nasdaq Stock Market LLC ("Nasdaq") indicating that as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the "Quarterly Report"), the Company no longer complies with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1). The notice has no immediate impact on the listing of the Company's securities, which will continue to trade on Nasdaq, subject to the Company's compliance with other applicable continued listing requirements.

Related Keywords

, Exchange Commission , Nasdaq Stock Market , Nasdaq , Purpose Acquisition Companies Spacs The Staff Statement , European Biotech Acquisition Corp , Audit Committee Of The Company , European Biotech Acquisition , Quarterly Report , Nasdaq Listing Rule , Reporting Considerations , Warrants Issued , Special Purpose Acquisition Companies , Staff Statement , Chief Accountant , Audit Committee , Late Filing , Biotech Acquisition , European , Biotech , Cquisition , Orp , Eceives , Xpected , Notification , Rom , Elated , Delayed , Uarterly , Report , பரிமாற்றம் தரகு , நாஸ்டாக் ஸ்டாக் சந்தை , நாஸ்டாக் , தணிக்கை குழு ஆஃப் தி நிறுவனம் , ஐரோப்பிய பயோடெக் கையகப்படுத்தல் , காலாண்டு அறிக்கை , நாஸ்டாக் பட்டியல் ஆட்சி , சிறப்பு நோக்கம் கையகப்படுத்தல் நிறுவனங்கள் , ஊழியர்கள் அறிக்கை , தலைமை கணக்கர் , தணிக்கை குழு , தாமதமாக தாக்கல் , ஐரோப்பிய , இோதேச் , ரோம் , உற்சாகமானது ,